Home / Precision Medicine

Precision Medicine

ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK

BURLINGTON, Mass.–(BUSINESS WIRE)–ArQule, Inc. (Nasdaq:ARQL), today announced the publication of preclinical study data for ARQ 531, the Company’s rationally-designed, reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). The studies, published in Cancer Discovery, were conducted in collaboration with researchers at The Ohio State University. Data from …

Read More »

Premier Partners with Progknowse to Develop Precision Medicine Analytics

CHARLOTTE, N.C. & TYSONS, Va.–(BUSINESS WIRE)–Premier Inc. (NASDAQ: PINC), a healthcare improvement company, is partnering with Progknowse, Inc. to develop a clinical and genomic data set for use within the PremierConnect® performance improvement platform to develop new predictive analytics capabilities that support precision medicine and personalized care delivery. Premier and Progknowse …

Read More »

Foundation Medicine Publishes New Data Supporting Blood Tumor Mutational Burden as a Novel Predictor of Response to Cancer Immunotherapy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, today announced the publication of the results of a large study demonstrating that its novel, investigational assay to measure blood tumor mutational burden (bTMB) can help predict response to the anti-PD-L1 immunotherapy, atezolizumab, (TECENTRIQ®) in patients with previously treated non-small cell lung cancer (NSCLC). The study, …

Read More »

Newly Characterized Molecule Offers Possibilities for Novel Alzheimer’s Treatments

Alzheimer’s disease is an increasingly prevalent, neurodegenerative condition that erodes memory and other cognitive functions. Treatments for this complex disease have been elusive, although researchers have previously uncovered its main biological features: amyloid-beta plaques and tau tangles. A study by researchers from Brigham and Women’s Hospital (BWH), recently published in Acta …

Read More »

Biocept and UC San Diego Moores Cancer Center Partner to Study Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy

SAN DIEGO, July 23, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will work with Moores Cancer Center at UC San Diego Health to conduct two clinical studies in patients with …

Read More »

Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers

A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international research team reports in JAMA Oncology. “This simple blood test demonstrates the potential of biomarker-based risk assessment …

Read More »

Otsuka to Expand its Pipeline of Antibody-Based Therapies through its $430 Million Acquisition of Visterra

TOKYO & WALTHAM, Mass.–(BUSINESS WIRE)–Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Visterra, Inc. (Visterra) announce that they have entered into a definitive merger agreement pursuant to which Otsuka will acquire Visterra for approximately USD 430 million in an all-cash transaction. The Otsuka and Visterra boards of directors have approved the transaction. …

Read More »

Discovery of New Biomarker Could Provide Personalized Treatment Options for Bladder Cancer

A potential new target for treatment has been identified in an aggressive form of bladder cancer, Mount Sinai researchers report. The cancer, called p53-like bladder cancer, is named after an active gene signature it is associated with. It is often particularly aggressive, though individual prognoses can vary quite a bit. …

Read More »

Catabasis Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition and Target Engagement in DMD

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new NF-kB inhibition biomarker results showing edasalonexent target engagement in the MoveDMD Phase 2 trial and open-label extension in boys affected by Duchenne muscular dystrophy (DMD). NF-kB is a fundamental driver of disease progression in DMD. These results add …

Read More »

Pancreatic Cancer Patients with BRCA Mutation may Benefit from Targeted Drug

A physician-scientist at the University of Arizona Cancer Center investigated a novel treatment for pancreatic cancer patients whose tumors exhibited a harmful genetic mutation. The results, in which a type of drug called a PARP inhibitor showed early promise in treating pancreatic cancer in patients with mutations in the BRCA …

Read More »